Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4534_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
27 Мб
Скачать
33 Airway Inammation: United Airway inChildren
431
33.2 Pathophysiologic Mechanisms Underlying
theRelationship Between Rhinitis/Rhinosinusitis andAsthma
Local Mechanisms (1, 2, 3): Over the years, several local and systemic mecha­nisms explaining the interaction between the upper and lower airways have been proposed [1, 2, 4, 6]. These are summarized in Fig.33.1. Mouth Breathing (1): In individuals with rhinitis/rhinosinusitis, the nose may be obstructed, and mouth breathing is favored, thereby eliminating this vital upper airway defense mecha­nism. This abnormal breathing (excluding the passage of air through the sinus system and the loss of function of inamed/infected sinuses) compromises air warming, humidication, and purication from pollutants and irritants, allowing physical and chemical agents to have an impact on the lower airways [2, 6]. In addition, the impairment of air ltering in the presence of sinus disease may increase allergen load reaching the bronchi in allergic patients. Baraldi etal. have proposed a novel and intriguing pathogenetic hypothesis that nitric oxide, which is thought to have a modulating effect on bronchial tone and is an important host­defense molecule, is decreased during sinusitis, and that decreased physiologic autoinhalation may play a role in increasing bronchial reactivity and susceptibil­ity to infection [2, 6]. Aspiration of Nasal Contents (2): The concept that inam­matory secretions from the upper airway of patients with rhinitis or rhinosinusitis are aspirated into the lower airway with negative consequences has traditionally been regarded as one of the primary mechanisms underlying lower airway symp­toms. The few available studies, however, have not conclusively supported this hypothesis [2, 9]. Neural Reexes (3): The presence and signicance of a sinona­sal-bronchial reex, characterized by bronchoconstriction triggered by the activa­tion of a trigeminal afferent-vagal efferent neural pathway, remains a topic of debate in human studies, despite being extensively documented in animal models [6, 9]. Rolla etal. demonstrated that damage to the pharyngeal mucosa in patients with CRS (likely mediated by the drainage of inammatory mediators and cells and/or infected material) increased the sub-mucosal nerve’s exposure to irritants, thereby activating the reex arc [10].
Systemic (Immunological) Mechanisms (4): A large body of evidence sug­gests that allergic inammation developing in the respiratory mucosa (due to allergen and/or other irritant agent exposure) may result in systemic inamma­tory events and that the nose and bronchi are linked through the systemic circu­lation. The inammatory process in the airways is strengthened and spread beyond its initial site by the release of immune cells and mediators from the bone marrow and other lymphoid organs. Despite the potential variability in the underlying causes, it is widely believed that the primary factor responsible for immune-mediated inammatory mechanisms in both the upper and lower air­ways is the presence of widespread eosinophilic inltration of the inamed mucosa, which is attributed to a prevalent Th2 immune response [3, 4, 6] (Fig.33.1).
432
Fig. 33.1 Overview of the complex interplay between immunological (systemic) and local mechanisms (post-nasal drip, neural reexes, mouth breathing) in patients with asthma and rhinosinusitis, according to the United Airway Disease theory (*: prevalent inammation endotype)
M. Serbes et al.
33.3 Phenoendotypes ofUnited Airway Disease Based
onInflammation
The archetype of UAD is allergic asthma-allergic rhinitis, but emerging evidence suggests that UAD is a heterogeneous condition with multiple phenotypes (observ­able clinical characteristics) and endotypes (pathobiological mechanisms). To improve outcomes in the classication and management of UAD, currently known phenoendotypes of UAD are proposed, in which pathophysiological mechanisms and biomarkers related to disease are identied and targeted for treatment (Table33.2) [8, 11].
33 Airway Inammation: United Airway inChildren
Table 33.2 Phenoendotypes of united airway disease (UAD) based on airway inammation type
Inammation type Endotype
Eosinophilic, Th2-high type
Allergic, systemic
Allergic, local IgE-mediated Local allergic
Non-allergic eosinophilic
Neutrophilic, Th2-low type
CRSwNP chronic rhinosinusitis with nasal polyps, CRSsNP chronic rhinosinusitis without nasal polyps, FENO fractional exhaled nitric oxide, TSLP thymic stromal lymphopoietin, COPD chronic obstructive pulmonary disease
a
Serum normal periostin level is 10ng·mL−1; a higher level identies an inammatory status. Blood and sputum eosinophil count of >2% or >300 cells/uL identies airway eosinophilia (blood eosinophil count <150 cells/uL indicates low likelihood of airway eosinophilia), sputum neutro­phil count 65% or >500 cells/104mL identies airway neutrophilia (cut-off <40% indicates low likelihood of airway neutrophilia). A FENO value <25 ppb (<20 ppb in children) is considered normal, while levels >50ppb (>35ppb in children) are indicative of eosinophilic inammation. Elevated serum total IgE levels (IgE >30 and <1500IU/mL) and positive specic IgE to at least one aeroallergen identify allergic inammation in children (age 6years) [8, 11, 12]
Th2, IL-4, IL-5, IL-13
IgE-mediated Allergic
IL-25, IL-33, TSLP, group 2 innate lymphoid cells (ILC2)
Th1, Th17, IL-17
Clinical phenotype Lower airway Upper airway CRSwNP Eosinophilic
asthma
Allergic
rhinitis
rhinitis
Non-allergic rhinitis with eosinophilia
CRsNP, İnfectious rhinitis
asthma
Intrinsic asthma
Adult-onset eosinophilic asthma
Neutrophilic asthma, COPD
Assessment method/ biomarker
Blood periostin, high FENO, sputum, and blood eosinophilia
Blood total IgE and specic IgE, skin prick tests
Local nasal and bronchial mucosa­specic IgE
Blood periostin, high FENO, sputum, and blood eosinophilia
Blood IL-8 and IL-17, sputum neutrophilia
a
433
33.4 Pathways ofAirway Inflammation inUnited
Airway Disease
The role of airway inammation in the development of UAD is signicant and is frequently triggered by the activation of the airway epithelium due to various environmental factors such as microbes (including respiratory viruses and bacte­ria), pollutants, and allergens. It is a dynamic trait that changes over time and is inuenced by factors such as treatment, infection, environmental exposures, and disease progression [12, 13]. The identication of the pathways of airway inam­mation, which encompass intricate, interconnected, and overlapping cascades regulated by various proinammatory cytokines, has yielded crucial and transfor­mative knowledge regarding the specic endophenotypes of UAD [1, 11, 12]. To date, airway inammation in the upper and lower airways is classied into 2 spe­cic molecular pathways called Th2-high type (eosinophilic) and Th2-low type (neutrophilic).
434
M. Serbes et al.
Th2-high inammation is caused by both the adaptive and innate immune systems and contributes to the pathophysiology of several chronic upper and lower airway dis­eases, including asthma, COPD, CRSwNP, and allergic rhinitis [11, 14]. Th2 cells and group 2 innate lymphoid cells (ILC2) drive type 2 inammation by producing type 2 cytokines such as interleukin (IL)-4, IL-5, and IL-13, as well as other inammatory mediators [11, 14]. In the pathophysiology of type 2 inammatory airway diseases, type 2 cytokines play a variety of roles. IL-5 is essential for the differentiation, maturation, mobilization, and survival of IL-5R+ eosinophil progenitors in the bone marrow. Furthermore, IL-5 promotes the development of other type 2 cells, which include mast cells and basophils [15]. Both IL-4 and IL-13 are involved in B-cell class switching and IgE production, which results in basophil and mast cell degranulation and the release of proinammatory mediators, as well as barrier disruption and tissue remodeling [7, 11,
16]. Goblet-cell hyperplasia, mucus production, smooth muscle contractility, and hyper-
plasia are all impacted by IL-13 [11, 16]. Additionally, the development of mucus plugs as a result of mucus production is linked to IL-13-mediated damage to the epithelial barriers [17]. The trafcking of eosinophils to tissues is mediated by IL-4, IL-13, and IL-5 [11, 1416]. Clinical symptoms of these common pathophysiological effects, which are caused by type 2 inammation, include nasal polyps, loss of smell, nasal obstruction in allergic rhinitis and CRSwNP [18, 19], impaired lung function, wheezing, shortness of breath, chest tightness, and coughing in asthma [20]. Interleukin-5- and interleukin-13-producing group 2 innate lymphoid cells (ILC2s) have been identied as a novel subset of lymphocytes. These cells possess the ability to induce eosinophilic inammation independently of adaptive immunity, including Th2 cells, B cells, and IgE antibodies. ILC2s are stimulated by cytokines IL-25, IL-33, and thymic stromal lym­phopoietin (TSLP) that are derived from epithelial cells. These cytokines are released by epithelial cells in response to damage caused by various stimuli such as microbiota and pollutants [11, 1416]. The corresponding phenoendotype in upper airways has been termed non-allergic rhinitis with eosinophilia syndrome (NARES) while termed non­allergic eosinophilic asthma in the lower airways in UAD (Table33.2).
Th2-low inammation is mainly characterized by neutrophils in nasal and bron­chial mucosa [5, 21, 22]. Infections or chronic irritation, such as air pollution, can cause neutrophilic inammation. This causes innate immune system dysregulation and activa­tion of the IL-17 pathway, as well as neutrophil recruitment to the nasal and bronchial mucosa, which is known to be mediated by IL-8 [21, 22]. Furthermore, it has been observed that the type 1 immune response, metabolic and epigenetic factors, as well as the activation of the epithelial-mesenchymal trophic unit, can contribute to signicant remodeling processes in the absence of inammation. These factors have been recog­nized as inuential elements in modulating neutrophilic inammation [22, 23].
33.5 The Role ofAirway Epithelium inUnited Airway Disease
This knowledge has been augmented by the realization of the signicance of air­way epithelium in inammatory processes. The airway epithelium serves as a protective barrier and environmental sensor to triggers (allergens, pollutants,
33 Airway Inammation: United Airway inChildren
435
smoking, etc.) and is the rst line of defense against insults inhaled. By stimulat­ing innate and adaptive immune reactions, it promotes immunity. After epithelial damage or immune cell activation, it quickly activates epithelial cells to produce “upstream” alarmin epithelial cytokines, including IL-25, IL-33, and thymic stro­mal lymphopoietin (TSLP). These cytokines—TSLP in particular—provide mas­ter regulation of Th2 inammation by guiding T-cell maturation along the Th2 cell pathway and triggering the production of downstream Th2 cytokines like IL-4, IL-5, and IL-13. Through Th1 and Th17, TSLP also contributes to inam­mation that is Th2-low (neutrophilic). Remodeling of the airways also begins with the airway epithelium. The direct effects of TSLP on broblasts may aid in the remodeling of the airways [24, 25].

33.6 Conclusion

Complex, interactive, and redundant cascades of proinammatory cytokines, including Th2-high, eosinophilic and Th2-low, neutrophilic inammation, mediate airway inammation in UAD.Consider united airway disease (UAD) in the differ­ential diagnosis for patients presenting with both upper and lower airway inamma­tory diseases. The research and efforts to better understand the pathophysiology, identify clinically useful diagnostic markers, and characterize inammatory endo­types will result in more effective targeted therapeutics for individuals presenting with UAD.

References

1. Bachert C, Luong AU, Gevaert P, et al. The unied airway hypothesis: evidence from specic intervention with anti-IL-5 biologic therapy. J Allergy Clin Immunol Pract. 2023;11(9):2630–41. S2213-2198(23)00547-0. https://doi.org/10.1016/j.jaip.2023.05.011.
2. de Benedictis FM, Bush A.Janus looks both ways: how do the upper and lower airways inter­act? Paediatr Respir Rev. 2020;34:59–66. https://doi.org/10.1016/j.prrv.2019.06.004.
3. Ahmad JG, Marino MJ, Luong AU.Unied airway disease: future directions. Otolaryngol Clin North Am. 2023;56(1):181–95. https://doi.org/10.1016/j.otc.2022.09.014.
4. Poddighe D, Brambilla I, Licari A, Marseglia GL.Pediatric rhinosinusitis and asthma. Respir Med. 2018;141:94–9. https://doi.org/10.1016/j.rmed.2018.06.016.
5. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF.Endotype-driven treat­ment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22. https://doi.org/10.1186/
s13601- 017- 0157- 8.
6. Kanda A, Kobayashi Y, Asako M, Tomoda K, Kawauchi H, Iwai H.Regulation of interaction between the upper and lower airways in United Airway disease. Med Sci (Basel). 2019;7(2):27.
https://doi.org/10.3390/medsci7020027.
7. Samitas K, Carter A, Kariyawasam HH, Xanthou G.Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy. 2018;73(5):993–1002. https://doi.org/10.1111/all.13373.
8. Yii ACA, Tay TR, Choo XN, Koh MSY, Tee AKH, Wang DY.Precision medicine in united airways disease: a “treatable traits” approach. Allergy. 2018;73(10):1964–78. https://doi.
org/10.1111/all.13496.
436
9. Lluncor M, Barranco P, Amaya ED, etal. Relationship between upper airway diseases, exhaled nitric oxide, and bronchial hyperresponsiveness to methacholine. J Asthma. 2019;56(1):53–60.
https://doi.org/10.1080/02770903.2018.1429465.
10. Rolla G, Colagrande P, Scappaticci E, et al. Damage of the pharyngeal mucosa and hyper­responsiveness of airway in sinusitis. J Allergy Clin Immunol. 1997;100(1):52–7. https://doi.
org/10.1016/s0091- 6749(97)70194- 5.
11. Maspero J, Adir Y, Al-Ahmad M, etal. Type 2 inammation in asthma and other airway dis­eases. ERJ Open Res. 2022;8(3):00576–2021. https://doi.org/10.1183/23120541.00576- 2021.
12. De Filippo M, Votto M, Licari A, etal. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Rev Respir Med. 2021;15(10):1303–16. https://doi.org/10.108
0/17476348.2021.1937132.
13. Ricciardolo FLM, Guida G, Bertolini F, Di Stefano A, Carriero V. Phenotype overlap in the natural history of asthma. Eur Respir Rev. 2023;32(168):220201. https://doi.org/10.118
3/16000617.0201- 2022.
14. Busse WW, Viswanathan R.What has been learned by cytokine targeting of asthma? J Allergy Clin Immunol. 2022;150(2):235–49. https://doi.org/10.1016/j.jaci.2022.06.010.
15. Kuruvilla ME, Lee FE, Lee GB.Understanding asthma phenotypes, endotypes, and mecha­nisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–33. https://doi.org/10.1007/
s12016- 018- 8712- 1.
16. Akdis CA, Arkwright PD, Brüggen MC, etal. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–605. https://doi.org/10.1111/all.14318.
17. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airow obstruction. J Clin Invest. 2018;128(3):997–1009. https://doi.
org/10.1172/JCI95693.
18. Takabayashi T, Schleimer RP.Formation of nasal polyps: the roles of innate type 2 inam­mation and deposition of brin. J Allergy Clin Immunol. 2020;145(3):740–50. https://doi.
org/10.1016/j.jaci.2020.01.027.
19. Wise SK, Damask C, Roland LT, etal. International consensus statement on allergy and rhi­nology: allergic rhinitis—2023. Int Forum Allergy Rhinol. 2023;13(4):293–859. https://doi.
org/10.1002/alr.23090.
20. Manti S, Licari A, Leonardi S, Marseglia GL.Management of asthma exacerbations in the paediatric population: a systematic review. Eur Respir Rev. 2021;30(161):200367. https://doi.
org/10.1183/16000617.0367- 2020.
21. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–75. https://doi.org/10.1111/cea.12880.
22. Hammad H, Lambrecht BN.The basic immunology of asthma [published correction appears in Cell. 2021 Apr 29;184(9):2521-2522]. Cell. 2021;184(6):1469–85. https://doi.org/10.1016/j.
cell.2021.02.016.
23. Fang L, Sun Q, Roth M.Immunologic and non-immunologic mechanisms leading to airway remodeling in asthma. Int J Mol Sci. 2020;21(3):757. https://doi.org/10.3390/ijms21030757.
24. Jakwerth CA, Ordovas-Montanes J, Blank S, Schmidt-Weber CB, Zissler UM.Role of respi­ratory epithelial cells in allergic diseases. Cells. 2022;11(9):1387. https://doi.org/10.3390/
cells11091387.
25. Frey A, Lunding LP, Ehlers JC, Weckmann M, Zissler UM, Wegmann M.More than just a bar­rier: the immune functions of the airway epithelium in asthma pathogenesis. Front Immunol. 2020;11:761. https://doi.org/10.3389/mmu.2020.00761.
M. Serbes et al.

Pediatric Allergic Rhinitis: Otolaryngology Perspective

MertCemalGökgöz, CemalCingi, andGabrielaKopacheva-Barsova

34.1 Introduction

Pediatric nasal obstruction is among the most common reasons for referral to pedi­atric otolaryngologists [1]. During the neonatal period and infancy, congenital causes are the most common causes of nasal obstruction, while in the pediatric age group in advanced ages, allergic, inammatory, and infectious rhinitis come to the fore as the primary causes [1]. Allergic causes are not considered in the foreground in nasal congestion in the rst 2years of age, mainly since there is insufcient time for allergen exposure [2]. The presence of at least two of the complaints of nasal congestion, rhinorrhea, sneezing, and itching accompanying the inammation of the nasal epithelium is sufcient for diagnosing rhinitis [3, 4]. Similar complaints may also occur in the presence of adenoid hypertrophy, acute and chronic sinusitis, deviation of the septum, or nasal polyp, which are other causes of nasal obstruction [5]. Allergic rhinitis is the most common chronic disease of childhood and hurts the quality of life regarding physical, social, and psychological well-being [6]. Allergic rhinitis leads to impaired sleep, daytime sleepiness, concentration impairment, and impaired cognitive functions, decreasing school success and impairing the quality of life for the child and the family. Allergic rhinitis is frequently caused by IgE­mediated early and late-phase hypersensitivity response to inhalant allergens [6].
34
M. C. Gökgöz Department of Otorhinolaryngology, Manisa City Hospital, Manisa, Turkey
C. Cingi (*) Medical Faculty, Department of Otorhinolaryngology, Eskisehir Osmangazi University, Eskisehir, Turkey
G. Kopacheva-Barsova Faculty of Medicine, Department of Otorhinolaryngology, Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024 H. Yüksel et al. (eds.), Pediatric Airway Diseases, Comprehensive ENT,
https://doi.org/10.1007/978-3-031-74853-0_34
437
438
Animal sources such as house dust, mites, pollen, cats and dogs, molds, and food allergies, which are increasingly common, can be stated as these allergens [7].
M. C. Gökgöz et al.

34.2 Epidemiology

34.2.1 Prevalence
In recent years, there has been an increase in the majority of allergic rhinitis, asthma, and atopic dermatitis. Environmental factors and lifestyle changes, diet changes, increased hygiene hypothesis, increased exposure to indoor antigens, and environ­mental toxins can be expressed as the reason for this increase [8]. In a study con­ducted in developed countries, the prevalence of allergic rhinitis has reached up to 50% [9]. Although the prevalence is higher in high-income countries, symptom scores reach higher levels in low- and middle-income countries [10]. Based on the study conducted by The International Study of Asthma and Allergies in Childhood in 98 countries and nearly 1.2 million children, the prevalence of allergic rhinitis is
8.5% in the 6–7 age group, while it rises to 14.6% in the 13–14 age group [11].
Regarding the prevalence of comorbid diseases, 20% of patients with asthma have allergic rhinitis, while 40% of patients diagnosed with allergic rhinitis have asthma [4].
34.2.2 Risk factors
Risk factors include family history, being male, being the rst child in the family, maternal and paternal smoking, systemic antibiotic use at an early age, especially indoor allergen exposure, increased hygiene status, having a serum IgE level of >100IU/mL before 6years of age and the presence of allergen-specic IgE [8, 12]. In addition to that, exposure to farm animals, air pollution, and high-intensity sports in adolescence can be added to the risk factors [13]. The same risk factors often apply to asthma and atopic dermatitis.
34.3 Etiology andPathogenesis
34.3.1 Classical Pathway
Allergen-specic IgE antibodies, formed due to previous allergen exposure, lead to the release of inammatory mediators by binding to mast cells located in the respi­ratory mucosa and basophils in the circulation. Histamine, leukotrienes, and prosta­glandins released by mast cells cause clinical ndings by secreting platelet-activating factors and bradykinin. Moreover, the release of eosinophilic mediators increases inammation. While the early phase occurs 15–30min following allergen exposure, the late response peaks after 6–12h.
34 Pediatric Allergic Rhinitis: Otolaryngology Perspective
439
34.3.2 Nasal Pathway
The nasal mucosa is the rst line of defense against respiratory bacteria, viruses, and allergens. It achieves this line of protection through the immune response to the deteriorations in the mucosal integrity; in this way, it initiates protective inamma­tory processes. The allergic immune reaction begins sensitizing when an allergen substance is encountered without an immune clinical response. At this stage, den­dritic cells in the nasal mucosa present the allergen to CD+ T cells. Subsequently, CD+ T cells transform into allergen-specic type 2 T helper cells. B cells are trans­formed into allergen-specic IgE-producing plasma cells upon B cell activation. Circulating IgE binds with high afnity to its receptors located on mast cells and basophils. This process ends with allergen-specic T helper cells and B cells form­ing memory against this allergen.
In the pathophysiology of allergic rhinitis, respiratory allergens disrupt epithelial integrity through protease enzyme activity, stimulate previously sensitive receptors, and result in an allergen-specic response. The immune response is initiated by releasing IL (Interleukin)-33, thymic stromal lymphopoietin (TSLP), or IL-25 [14]. These, in turn, cause the release of IL-5, IL-13, and IL-4 cytokines, which provide IgE-mediated immune response and mucosal inammation. It is considered that pollutants, irritants, and infectious agents (Staphylococcus aureus or viruses) could impact this pathway [15]. S. aureus is responsible for producing enterotoxins with superantigenic properties and is a frequently observed bacterium in the respiratory tract. Immune response to superantigens can be seen in both B and T cells. In the presence of S. aureus in the nasal cavity in patients with allergic rhinitis, allergic symptoms may be felt more severely with superantigens [16].
34.4 Diagnosis, Physical Examination, andDiagnostic Tests
34.4.1 Diagnosis andHistory
Patient history, physical examination, and allergy tests are primary in diagnosing allergic rhinitis. In the diagnosis of allergic rhinitis, as in every disease, the account to be taken from the patient in the pediatric age group and their parent is crucial in making the correct diagnosis and for patient management. There are issues to be considered in the history and physical examination when diagnosing rhinitis, deter­mining its type, differentiating accompanying pathologies, and other diagnoses [17, 18].
Before the physical examination, the physician should also shed light on the points related to rhinitis, which might be overlooked by the parent, by asking various queries. The patient’s age, since when the disease has been present, its frequency, duration, and seasonal characteristics, whether it continues throughout the year, the presence of exacerbations, whether there is a condition that causes the symptoms to occur, the impact of environmental factors originating from home or school, the presence of symptoms accompanying nasal symptoms, daily activities, school performance, sleep
440
M. C. Gökgöz et al.
patterns, whether it affects the patient’s and his parent’s quality of life, and the pres­ence of family history should be questioned. If any, the patient’s previous allergy tests, diagnostic tests, imaging tests, the company of medications or other treatments received, and the history of surgery should be questioned [19] (Table34.1).
34.4.2 Physical Examination
In the physical examination to be performed by an otolaryngologist, particularly, detection and differentiation of the accompanying diseases are of great importance. During the inspection, “allergic salute- transverse external crease,” “Dennie-Morgan lines,” allergic shiners (dark eye shadows, reecting venous pooling in the lid ves­sels.), and frequent throat clearing movements, which are indicators of postnasal dis­charge, can be noticed. Another critical point to be evaluated during the inspection is the open-mouth breathing pattern due to chronic nasal obstruction, elongated facial appearance (adenoid facies), and accompanying dental malocclusion problems. A complete ear, nose, oropharynx, oral cavity, and neck examination should be per­formed in the physical examination. In the ear examination, dullness or retraction of the tympanic membrane, air-uid levels as a result of Eustachian dysfunction due to allergic rhinitis, presence of serous otitis, and accompanying hearing loss should be evaluated via audiometric tests and tympanometry. In the nasal examination, the pres­ence and consistency of nasal discharge in anterior rhinoscopy, septum pathologies, hypertrophies of the inferior turbinate and middle turbinate, pallor or a pale bluish hue accompanied by mucosal edema, the presence of nasal polyps or foreign bodies, crusting, and perforation can be evaluated. Albeit anterior rhinoscopy is a simple pro­cedure to perform, patient and parent compliance is signicant for nasal endoscopy. It is more challenging to apply in children younger than 2years old. The process can be performed via rigid or exible 2.7–4 mm endoscopes. Local anesthetic and
Table 34.1 Clinical symptoms and relation with age groups in pediatric ages
Age groups Pre-
Clinical symptoms Rhinorrhea (watery, discolored) x X X Pruritis/itching (allergic salute, allergic crease, itchy mouth
and throat) Sneezing x X X Nasal congestion x X X Cough (with/without asthma) >2years X X Eustachian dysfunction (due to nasal congestion) x X Sleep problems (due to nasal obstruction) >2years x X Rhinosinusitis related symptoms (Nasal congestion, purulent
nasal discharge, cough, facial pain and pressure, mucosal edema, polyp)
Prolonged respiratory tract infections >2years x X Irritability, poor school performance x x
school School Adolescent
x X X
x X